West Europe
United KingdomGSK Q3 2026 Earnings Report
GSK announced its Q3 2026 earnings, reporting revenues slightly above estimates but with Shingrix and Vaccines sales below expectations, and reaffirmed its 2026 core EPS guidance.
Background
Pharmaceutical companies like GSK operate within a highly regulated global market, balancing drug development costs with public health needs and investor expectations. Quarterly earnings reports provide insight into the financial health and strategic direction of these major healthcare providers.
Quorum · collective opinions
GSK Q3 2026 Earnings Report
First report 6h agoLast update 6h agoThe earnings report for GSK's Q3 2026 is presented factually, detailing revenue, EPS, and sales figures against estimates.
GSK Q3 2026 Earnings Report
First report 6h agoLast update 6h agoGSK's Q3 2026 revenue exceeded estimates, but sales for key products like Shingrix and other vaccines fell short, leading to a reaffirmation of the lower end of their 2026 core EPS guidance.
GSK Q3 2026 Earnings Report
First report 6h agoLast update 6h agoFinancial news sources are reporting GSK's Q3 2026 earnings, highlighting key figures like revenue, EPS, and vaccine sales.
iWitness comments
No comments yet — be the first to weigh in.